remdesivir Archive — Page 1 of 1

Portrait of a smiling man wearing glasses, a white medical coat, and a red tie.
May 10, 2022

Resistance to COVID-19 drug detected in lab study

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

By Bill Snyder
Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
October 26, 2020

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

By Bill Snyder
Head-and-shoulders portrait of a smiling bearded man wearing a gray shirt and dark tie against a brown background.
July 22, 2020

New data offer insights on COVID treatments for people with cancer

Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

By Tom Wilemon
Close-up of a high-tech laboratory interface displaying the words “COVID-19” and “VIRUS,” with colorful circuit-like lines and data graphics.
July 9, 2020

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

By Bill Snyder
Green-gloved laboratory worker holds two small tubes containing clear liquid over a blurred lab coat.
June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

By Bill Snyder
Close-up of a high-tech laboratory interface displaying the words “COVID-19” and “VIRUS,” with colorful circuit-like lines and data graphics.
April 29, 2020

Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

By Craig Boerner